Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
1,561 results
  • Clinical trials in autism spectrum disorder: evidence, challenges and future directions. [Journal Article]
  • COCurr Opin Neurol 2018 Jan 31
  • Anagnostou E
  • CONCLUSIONS: Several compounds have evidence for the treatment of co-occurring symptoms in children and youth with ASD, although pharmacological interventions for core symptoms are still lacking. Identifying the various biologies underling ASD and developing biomarkers that stratify biologically homogeneous populations are both necessary to realize the promise of precision medicine in ASD.
  • Selective noradrenaline reuptake inhibitors for schizophrenia. [Review]
  • CDCochrane Database Syst Rev 2018 Jan 25; 1:CD010219
  • Matthews PRL, Horder J, Pearce M
  • CONCLUSIONS: Our results provide tentative very low quality evidence that compared to placebo, NRIs (specifically reboxetine) may have a benefit on the negative symptoms of schizophrenia. Limited evidence also suggests that NRIs have no effect on the positive symptoms of schizophrenia or cognitive functioning. NRIs appear generally well tolerated with no real differences in adverse effects such as nausea noted between NRIs and placebo. However, these results are based on short-term follow-up and are poor quality - there is need for more good-quality evidence. A large RCT of reboxetine over a longer period of time, focusing specifically on negative and cognitive symptoms as well as more detailed and comprehensive reporting of outcomes, including adverse events, is required.
  • [A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam]. [Journal Article]
  • ZNZh Nevrol Psikhiatr Im S S Korsakova 2017; 117(11. Vyp. 2):75-79
  • Kupriyanova TA, Koren EV, Alabusheva NN
  • CONCLUSIONS: A short-term positive therapeutic dynamics was observed when introducing hopantenic acid (pantogam) augmentation strategy to existing atomoxetine therapy. Qualitative improvements in children's state were found not only in the ability to control symptoms but also in their social functioning levels and quality of life. The proposed therapeutic strategy can help to improve treatment outcomes for children with certain clinical forms of hyperkinetic behavior disorder.
  • Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy. [Journal Article]
  • JCJ Child Adolesc Psychiatr Nurs 2018 Jan 19
  • Hogan MK, Rao NP
  • CONCLUSIONS: Genetic testing as a prescriptive tool is not indicated for all medications; however, potential drug-drug interactions, narrow therapeutic drug index, and side effect toxicity contribute to the need for testing. An understanding of CYP450 metabolism and drug interaction as well as metabolism phenotypes should inform prescribing and dosing psychotropic medications.
New Search Next